Recently reported TTBK1 inhibitors target not only TTBK1 but also TTBK2, which loss of function mutation is known to lead to spinocerebellar ataxia 11 due to the similarity of catalytic domains between these two tau-kinases. The gene discussed is TTBK2; the disease is spinocerebellar ataxia type 11.